Study supports radiomics in predicting immunotherapy effectiveness in advanced NSCLC
In a real-world study, multimodal artificial intelligence models outperform PD-L1 across key endpoints
AI model boosts survival prediction accuracy after neoadjuvant chemotherapy in breast cancer
A study compared the performance of different models using routinely collected clinicopathological data from women with HR-positive/HER2-negative breast cancer
Shaping the use of AI in oncology
ESMO plays a central role in developing long-lasting recommendations for a safe and effective use of artificial intelligence supporting oncology stakeholders
Artificial intelligence is expediting the development of therapeutic immunotherapies
AI-driven approaches can help to design minibinders, which may bring new T-cell receptor-based therapies closer to the clinic
Bridging the interpretation gap in cancer genomics – the next frontier for ai in oncology
Can artificial intelligence finally unlock the full potential of cancer genomics? Discover how new digital tools are closing the gap between data and clinical action in oncology.
AI-powered three-dimensional tumour pathology
Computational models can overcome current limitations of 3D analysis of tumour samples
AI tool outperforms manual PD-L1 scoring in a study
Integrating artificial intelligence into pathology routine workflows could optimise patient selection for immunotherapy
The first ESMO guidance for AI-based biomarkers
In a newly released framework paper, ESMO defines criteria for assessing and implementing AI-based biomarkers in oncology
Artificial intelligence as a reliable research partner
Extensive research is focusing on the development of tools that may enhance drug development and personalised oncology in the near future
AI may be key to streamline patient allocation to clinical trials
As a proof of concept, an AI-powered large language model matching platform shows promise in patient selection